This intersection of cancer genetic predisposition and precision medicine is exemplified by PARP inhibitors as potential therapies for individuals carrying pathogenic or likely pathogenic variants in BRCA1/2 genes, initially effective in treating ovarian cancer and subsequently in breast, prostate, and pancreatic cancers [39]. The gene discussed is BRCA1; the disease is ovarian cancer.